Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- FPMAJ Proposes Fast Track System -1-
December 24, 2001
- Nearly 50% of Physicians Want Increased MTX Doses for RA: Society Meeting
December 24, 2001
- FPMAJ Proposes Fast Track System -2-
December 24, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
December 24, 2001
- Imigran Tablets Selling Better than Expected: GSK
December 24, 2001
- Health Minister Concerned About Higher Price of Reagent for Blood Test
December 24, 2001
- BUSINESS NEWS IN BRIEF
December 24, 2001
- Sanko Junyaku: Microplate EIA System
December 24, 2001
- Tanabe to Continue Strategic Technical Alliances with Foreign Companies
December 24, 2001
- Sysmex Develops Hemocytometer for POC Use
December 24, 2001
- 33 JPMA Member Companies: Sales Up 2.4%, Profits Up 56.5%
December 24, 2001
- Pharmacia to Spin Off Stake in Monsanto
December 24, 2001
- Morishita Jintan: Sales Up 3.7%, Net Profits Plummet
December 24, 2001
- Sysmex to Make International Reagents Its 100%-owned Subsidiary
December 24, 2001
- JCR Pharmaceutical: Sales Down 9.0%, Profits Down 45.1%
December 24, 2001
- Arkray Adds Gastric Cancer as Test Item to Home Health Check
December 24, 2001
- Both Income, Expenses Decreased at Clinics
December 24, 2001
- Re-pricing Rule to Be Introduced for Medical Materials
December 24, 2001
- Medical Facilities Obtain Great Profits with Small Capital: Kenporen Study
December 24, 2001
- Iatron Develops New Reagent to Determine Blood Elastase-1
December 24, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…